HK1034913A1 - Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia. - Google Patents
Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia.Info
- Publication number
- HK1034913A1 HK1034913A1 HK01105732A HK01105732A HK1034913A1 HK 1034913 A1 HK1034913 A1 HK 1034913A1 HK 01105732 A HK01105732 A HK 01105732A HK 01105732 A HK01105732 A HK 01105732A HK 1034913 A1 HK1034913 A1 HK 1034913A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fibrate
- metformin
- preparation
- combination
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9801709A FR2774591B1 (fr) | 1998-02-12 | 1998-02-12 | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie |
PCT/EP1999/000614 WO1999040904A2 (en) | 1998-02-12 | 1999-01-30 | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the treatment of hyperglycemia |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1034913A1 true HK1034913A1 (en) | 2001-11-09 |
Family
ID=9522912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK01105732A HK1034913A1 (en) | 1998-02-12 | 2001-08-15 | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia. |
Country Status (28)
Country | Link |
---|---|
US (1) | US6372790B1 (id) |
EP (1) | EP1054665B1 (id) |
JP (1) | JP4767411B2 (id) |
KR (1) | KR100567608B1 (id) |
CN (1) | CN1151785C (id) |
AR (1) | AR018286A1 (id) |
AT (1) | ATE204754T1 (id) |
AU (1) | AU746821B2 (id) |
BR (1) | BRPI9907866B8 (id) |
CA (1) | CA2320039C (id) |
CZ (1) | CZ290101B6 (id) |
DE (1) | DE69900249T2 (id) |
DK (1) | DK1054665T3 (id) |
ES (1) | ES2162517T3 (id) |
FR (1) | FR2774591B1 (id) |
HK (1) | HK1034913A1 (id) |
HU (1) | HU224619B1 (id) |
ID (1) | ID26254A (id) |
MY (1) | MY118164A (id) |
NO (1) | NO328314B1 (id) |
PL (1) | PL196874B1 (id) |
PT (1) | PT1054665E (id) |
RU (1) | RU2207850C2 (id) |
SK (1) | SK283212B6 (id) |
TW (1) | TW518222B (id) |
UA (1) | UA70315C2 (id) |
WO (1) | WO1999040904A2 (id) |
ZA (1) | ZA991077B (id) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029314A1 (en) * | 1997-12-08 | 1999-06-17 | Bristol-Myers Squibb Company | Novel salts of metformin and method |
US6982281B1 (en) | 2000-11-17 | 2006-01-03 | Lipocine Inc | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
FR2796551B1 (fr) * | 1999-07-23 | 2003-07-25 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
FR2796940B1 (fr) * | 1999-07-26 | 2005-04-08 | Lipha | Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant |
US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
JP4879433B2 (ja) * | 2000-01-13 | 2012-02-22 | エミスフェアー・テクノロジーズ・インク | 活性剤を送達するための化合物および組成物 |
US6531158B1 (en) * | 2000-08-09 | 2003-03-11 | Impax Laboratories, Inc. | Drug delivery system for enhanced bioavailability of hydrophobic active ingredients |
JP4829411B2 (ja) * | 2001-02-23 | 2011-12-07 | キッセイ薬品工業株式会社 | C型慢性肝炎治療剤 |
GB0119480D0 (en) | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
KR100897890B1 (ko) | 2002-06-17 | 2009-05-18 | 인벤티아 헬스케어 피브이티. 엘티디. | 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법 |
EP1424070A1 (en) * | 2002-11-28 | 2004-06-02 | Fournier Laboratories Ireland Limited | Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides |
US8003690B2 (en) | 2002-12-13 | 2011-08-23 | Jagotec Ag | Topical nanoparticulate spironolactone formulation |
FR2851734B1 (fr) * | 2003-02-28 | 2006-06-09 | Galenix Innovations | Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede |
FR2858556B1 (fr) * | 2003-08-06 | 2006-03-10 | Galenix Innovations | Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation |
US8062664B2 (en) * | 2003-11-12 | 2011-11-22 | Abbott Laboratories | Process for preparing formulations of lipid-regulating drugs |
CN101897970A (zh) | 2003-12-19 | 2010-12-01 | 奥加生物药业(I.P.3)有限公司 | 用于治疗糖尿病的组合物和方法 |
EP1559419A1 (en) * | 2004-01-23 | 2005-08-03 | Fournier Laboratories Ireland Limited | Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention |
EP1714648A4 (en) * | 2004-02-09 | 2010-05-26 | Aska Pharm Co Ltd | COMBINATION DRUGS |
EP1591114A1 (en) * | 2004-03-12 | 2005-11-02 | Fournier Laboratories Ireland Limited | Use of metformin and orlistat for the treatment or prevention of obesity |
US20060286182A1 (en) * | 2005-06-21 | 2006-12-21 | Abeille Pharmaceuticals, Inc. | Synergistic cinnamon combinations and methods for enhancing insulin activity |
GB0602639D0 (en) * | 2006-02-09 | 2006-03-22 | Novartis Ag | Organic compounds |
BRPI0621942A2 (pt) | 2006-08-04 | 2011-10-18 | Aska Pharm Co Ltd | preparação que reduz uma concentração de um ácido graxo livre e/ou fibrinogênio no sangue, agente para redução da quantidade de um ácido graxo livre no sangue, agente para redução da quantidade de fibrinogênio no sangue, método de prevenção ou tratamento de hiper-acidemia de ácido graxo livre, sìndrome metabólica, diabetes tipo ii, complicações causadas por diabetes tipo ii, lipotoxicidade, metabolismo anormal de lipìdeos, intoleráncia à glicose, secreção prejudicada de insulina, gordura hepática, lipoproteinemia de hipo-alta densidade, ou trombose, e uso de uma preparação |
CN101342164B (zh) * | 2007-08-21 | 2011-04-20 | 阜新市仙鹤制药有限责任公司 | 苯扎贝特控释制剂及其制备方法 |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
ES2344183B1 (es) * | 2009-02-18 | 2011-06-10 | Italfarmaco, S.A. | Uso de agentes sensibilizantes a insulina por via vaginal. |
US9339458B2 (en) * | 2009-02-18 | 2016-05-17 | Itf Research Pharma, S.L.U. | Use of vaginal insulin sensitizing agents |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
JP2012171911A (ja) | 2011-02-22 | 2012-09-10 | Kao Corp | Ppar活性化剤 |
IN2015KN00076A (id) * | 2012-07-10 | 2015-07-31 | Thetis Pharmaceuticals Llc | |
US9382187B2 (en) * | 2012-07-10 | 2016-07-05 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
US8765811B2 (en) * | 2012-07-10 | 2014-07-01 | Thetis Pharmaceuticals Llc | Tri-salt form of metformin |
WO2015171516A1 (en) | 2014-05-05 | 2015-11-12 | Thetis Pharmaceuticals Llc | Compositions and methods relating to ionic salts of peptides |
WO2015183794A1 (en) | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
US9242008B2 (en) | 2014-06-18 | 2016-01-26 | Thetis Pharmaceuticals Llc | Mineral amino-acid complexes of fatty acids |
CN107074884A (zh) | 2014-06-18 | 2017-08-18 | 西蒂斯制药有限责任公司 | 活性剂的矿物质氨基酸复合物 |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
FR3050112B1 (fr) * | 2016-04-15 | 2020-09-04 | Soc Civ Immobiliere Gecinq | Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques |
CA3026264A1 (en) | 2016-06-03 | 2017-12-07 | Thetis Pharmaceuticals Llc | Compositions and methods relating to salts of specialized pro-resolving mediators |
WO2018058109A1 (en) * | 2016-09-26 | 2018-03-29 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
FR3056908B1 (fr) * | 2016-09-30 | 2019-04-19 | Nashpharm | Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie |
EP3544614A4 (en) | 2016-11-28 | 2020-08-05 | Lipocine Inc. | ORAL TESTOSTERONE UNDECANOATE THERAPY |
GB2599950A (en) * | 2020-10-16 | 2022-04-20 | Zentiva Ks | Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same |
WO2023119100A1 (en) * | 2021-12-22 | 2023-06-29 | Mankind Pharma Ltd. | Stable pharmaceutical compositions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4080472A (en) | 1974-03-22 | 1978-03-21 | Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. | Metformin 2-(p-chlorophenoxy)-2-methylpropionate |
FR2264525B1 (id) * | 1974-03-22 | 1977-11-04 | Expl Marques Brevets Et | |
DE3729209A1 (de) * | 1987-09-01 | 1989-03-09 | Boehringer Mannheim Gmbh | Verwendung von bezafibrat zur behandlung von diabetes |
JP3852621B2 (ja) * | 1992-01-21 | 2006-12-06 | あすか製薬株式会社 | 血管内皮細胞機能改善剤 |
EP0930882A2 (en) * | 1996-08-02 | 1999-07-28 | Institut Pasteur De Lille | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
-
1998
- 1998-02-12 FR FR9801709A patent/FR2774591B1/fr not_active Expired - Lifetime
-
1999
- 1999-01-30 UA UA2000095172A patent/UA70315C2/uk unknown
- 1999-01-30 EP EP99910169A patent/EP1054665B1/en not_active Expired - Lifetime
- 1999-01-30 HU HU0100801A patent/HU224619B1/hu active IP Right Grant
- 1999-01-30 US US09/601,618 patent/US6372790B1/en not_active Expired - Lifetime
- 1999-01-30 CZ CZ20002828A patent/CZ290101B6/cs not_active IP Right Cessation
- 1999-01-30 AU AU29233/99A patent/AU746821B2/en not_active Expired
- 1999-01-30 WO PCT/EP1999/000614 patent/WO1999040904A2/en active IP Right Grant
- 1999-01-30 PT PT81108560T patent/PT1054665E/pt unknown
- 1999-01-30 ID IDW20001765A patent/ID26254A/id unknown
- 1999-01-30 PL PL342665A patent/PL196874B1/pl unknown
- 1999-01-30 DE DE69900249T patent/DE69900249T2/de not_active Expired - Lifetime
- 1999-01-30 RU RU2000123567/14A patent/RU2207850C2/ru active
- 1999-01-30 CN CNB998029041A patent/CN1151785C/zh not_active Expired - Lifetime
- 1999-01-30 ES ES99910169T patent/ES2162517T3/es not_active Expired - Lifetime
- 1999-01-30 AT AT99910169T patent/ATE204754T1/de active
- 1999-01-30 KR KR1020007008836A patent/KR100567608B1/ko not_active IP Right Cessation
- 1999-01-30 CA CA002320039A patent/CA2320039C/en not_active Expired - Lifetime
- 1999-01-30 SK SK1156-2000A patent/SK283212B6/sk not_active IP Right Cessation
- 1999-01-30 JP JP2000531156A patent/JP4767411B2/ja not_active Expired - Lifetime
- 1999-01-30 DK DK99910169T patent/DK1054665T3/da active
- 1999-01-30 BR BR9907866A patent/BRPI9907866B8/pt not_active IP Right Cessation
- 1999-02-09 MY MYPI99000445A patent/MY118164A/en unknown
- 1999-02-10 TW TW088102063A patent/TW518222B/zh not_active IP Right Cessation
- 1999-02-10 ZA ZA9901077A patent/ZA991077B/xx unknown
- 1999-02-12 AR ARP990100598A patent/AR018286A1/es active IP Right Grant
-
2000
- 2000-08-11 NO NO20004056A patent/NO328314B1/no not_active IP Right Cessation
-
2001
- 2001-08-15 HK HK01105732A patent/HK1034913A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA991077B (en) | Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia. | |
ZA200203368B (en) | Pharmaceutical composition comprising a combination of metformin and glibenclamide. | |
ZA200001159B (en) | Solid oral dosage form comprising a combination of metformin and glibenclamide. | |
HUP0104497A3 (en) | Benzamide derivatives, their preparation, medicaments containing them and their use | |
HK1034455A1 (en) | Oral pharmaceutical extended release dosage form. | |
HUP0200714A3 (en) | Pharmaceutical compounds, pharmaceutical compositions containing them and their use | |
HU0400409D0 (hu) | Fenofibrát-tartalmú, azonnal oldódó készítmény | |
HUP0004040A3 (en) | Pleuromutilin derivatives as antimicrobials, process for their preparation, pharmaceutical compositions, comprising thereof and their use | |
HUP0100101A3 (en) | Prostaglandin agonists, pharmaceutical compositions comprising thereof and their use | |
HUP0104579A3 (en) | Glp-1 analogues, pharmaceutical compositions comprising thereof and their use | |
HUP0204413A3 (en) | Quinazoline compounds, their preparation, their use and pharmaceutical compositions containing them | |
ZA200107983B (en) | New compounds, their preparation and use. | |
ZA973022B (en) | New pharmaceutical composition with anaesthetic effect. | |
HUP0203505A3 (en) | 2'-substituted 1,1'-biphenyl-2-carbonamides, and pharmaceutical compositions containing said compounds | |
HUP0103884A3 (en) | Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use | |
IL149139A0 (en) | Pharmaceutical compositions containing metformin and glyburide | |
PL343512A1 (en) | Thienylazolylalcoxyethanamines, their preparation and their application as medicaments | |
IL150383A0 (en) | Glyburide and pharmaceutical compositions containing the same | |
HUP0102255A3 (en) | Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use | |
HUP0203194A3 (en) | Phenylpiperazines, pharmaceutical compositions containing them and their use | |
HUP0203735A3 (en) | 4-pyridinyl-n-acyl-l-phenylalanines, pharmaceutical compositions containing them and their use | |
CZ2006533A3 (cs) | Amorfní ritonavir, způsoby jeho přípravy, jeho použití a farmaceutická kompozice ho obsahující | |
HRP950363A2 (en) | Novel chemical compound, its preparation and use as a drug | |
HK1035719A1 (en) | Azabicyclic compounds, pharmaceutical composition containing them and their medicinal use | |
HUP0001940A3 (en) | Benzisothiazole derivatives, their use and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PE | Patent expired |
Effective date: 20190129 |